SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hippel James
(Last) (First) (Middle)
614 MCKINLEY PLACE NE
(Street)
MINNEAPOLIS MN 55413
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 57,561 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $31.26 (1) 08/09/2024 Common Stock 189,156 189,156 D
Stock Options (Right to Buy) $44.33 (1) 08/08/2025 Common Stock 72,264 72,264 D
Stock Options (Right to Buy) $44.33 (1) 08/08/2025 Common Stock 96,356 96,356 D
Stock Options (Right to Buy) $47.6 (1) 08/07/2026 Common Stock 79,744 79,744 D
Stock Options (Right to Buy) $47.6 (1) 08/07/2026 Common Stock 106,324 106,324 D
Stock Options (Right to Buy) $66.97 (1) 08/05/2027 Common Stock 57,440 57,440 D
Stock Options (Right to Buy) $66.97 (1) 08/05/2027 Common Stock 33,300 33,300 D
Restricted Stock Units (2) (3) (3) Common Stock 12,876 0 D
Stock Options (Right to Buy) $66.97 (4) 08/05/2027 Common Stock 76,588 76,588 D
Restricted Stock Units (2) (5) (5) Common Stock 7,780 7,780 D
Stock Options (Right to Buy) $120.46 (5) 08/06/2028 Common Stock 30,400 30,400 D
Stock Options (Right to Buy) $120.46 (6) 08/06/2028 Common Stock 40,536 40,536 D
Restricted Stock Units (2) (7) (7) Common Stock 10,912 10,912 D
Stock Options (Right to Buy) $94.52 (7) 08/15/2029 Common Stock 33,916 33,916 D
Stock Options (Right to Buy) $94.52 (8) 08/15/2029 Common Stock 45,220 45,220 D
Restricted Stock Units (2) 08/15/2023 A 12,798 (9) (9) Common Stock 12,798 $0 12,798 D
Stock Options (Right to Buy) $84.61 08/15/2023 A 34,442 (9) 08/15/2030 Common Stock 34,442 $0 34,442 D
Stock Options (Right to Buy) $84.61 08/15/2023 A 45,923 (10) 08/15/2030 Common Stock 45,923 $0 45,923 D
Explanation of Responses:
1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
3. On 8/5/2023, the Board of Directors certified vesting of 12,876 performance RSUs.
4. Options to purchase 57,440 shares are vested. Options to purchase 19,148 shares vest on 8/5/2024.
5. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
6. Options to purchase 20,268 shares are vested. Options to purchase 10,136 shares vest on 8/6/2024 and options to purchase 10,134 shares vest on 8/6/2025.
7. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
8. Options to purchase 11,304 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026 and options to purchase 11,308 shares vest on 8/15/2024.
9. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
10. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/27, and options to purchase 11,480 shares vest on 8/15/2026.
/s/ Andrew Nick, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed 08/17/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.